Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women

Jane R. Schwebke, C. A. Gaydos, T. Davis, J. Marrazzo, D. Furgerson, S. N. Taylor, B. Smith, L. H. Bachmann, R. Ackerman, T. Spurrell, Daron Gale Ferris, C. A. Burnham, H. Reno, J. Lebed, D. Eisenberg, P. Kerndt, S. Philip, J. Jordan, N. Quigley

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Trichomoniasis is the most prevalent curable sexually transmitted disease (STD). It has been associated with preterm birth and the acquisition and transmission of HIV. Recently, nucleic acid amplification tests (NAAT) have been FDA cleared in the United States for detection of Trichomonas vaginalis in specimens from both women and men. This study reports the results of a multicenter study recently conducted using the Xpert TV (T. vaginalis) assay to test specimens from both men and women. On-demand results were available in as little as 40 min for positive specimens. A total of 1,867 women and 4,791 men were eligible for inclusion in the analysis. In women, the performance of the Xpert TV assay was compared to the patient infected status (PIS) derived from the results of InPouch TV broth culture and Aptima NAAT for T. vaginalis The diagnostic sensitivities and specificities of the Xpert TV assay for the combined female specimens (urine samples, self-collected vaginal swabs, and endocervical swabs) ranged from 99.5 to 100% and 99.4 to 99.9%, respectively. For male urine samples, the diagnostic sensitivity and specificity were 97.2% and 99.9%, respectively, compared to PIS results derived from the results of broth culture for T. vaginalis and bidirectional gene sequencing of amplicons. Excellent performance characteristics were seen using both female and male specimens. The ease of using the Xpert TV assay should result in opportunities for enhanced screening for T. vaginalis in both men and women and, hopefully, improved control of this infection.

Original languageEnglish (US)
JournalJournal of clinical microbiology
Volume56
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Trichomonas vaginalis
Nucleic Acid Amplification Techniques
Urine
Sensitivity and Specificity
Premature Birth
Infection Control
Sexually Transmitted Diseases
Multicenter Studies
HIV

Keywords

  • diagnosis
  • female
  • male
  • NAAT
  • trichomonas

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women. / Schwebke, Jane R.; Gaydos, C. A.; Davis, T.; Marrazzo, J.; Furgerson, D.; Taylor, S. N.; Smith, B.; Bachmann, L. H.; Ackerman, R.; Spurrell, T.; Ferris, Daron Gale; Burnham, C. A.; Reno, H.; Lebed, J.; Eisenberg, D.; Kerndt, P.; Philip, S.; Jordan, J.; Quigley, N.

In: Journal of clinical microbiology, Vol. 56, No. 2, 01.02.2018.

Research output: Contribution to journalArticle

Schwebke, JR, Gaydos, CA, Davis, T, Marrazzo, J, Furgerson, D, Taylor, SN, Smith, B, Bachmann, LH, Ackerman, R, Spurrell, T, Ferris, DG, Burnham, CA, Reno, H, Lebed, J, Eisenberg, D, Kerndt, P, Philip, S, Jordan, J & Quigley, N 2018, 'Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women', Journal of clinical microbiology, vol. 56, no. 2. https://doi.org/10.1128/JCM.01091-17
Schwebke, Jane R. ; Gaydos, C. A. ; Davis, T. ; Marrazzo, J. ; Furgerson, D. ; Taylor, S. N. ; Smith, B. ; Bachmann, L. H. ; Ackerman, R. ; Spurrell, T. ; Ferris, Daron Gale ; Burnham, C. A. ; Reno, H. ; Lebed, J. ; Eisenberg, D. ; Kerndt, P. ; Philip, S. ; Jordan, J. ; Quigley, N. / Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women. In: Journal of clinical microbiology. 2018 ; Vol. 56, No. 2.
@article{da95ba5367064412ac277d1b8d0b6f3d,
title = "Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women",
abstract = "Trichomoniasis is the most prevalent curable sexually transmitted disease (STD). It has been associated with preterm birth and the acquisition and transmission of HIV. Recently, nucleic acid amplification tests (NAAT) have been FDA cleared in the United States for detection of Trichomonas vaginalis in specimens from both women and men. This study reports the results of a multicenter study recently conducted using the Xpert TV (T. vaginalis) assay to test specimens from both men and women. On-demand results were available in as little as 40 min for positive specimens. A total of 1,867 women and 4,791 men were eligible for inclusion in the analysis. In women, the performance of the Xpert TV assay was compared to the patient infected status (PIS) derived from the results of InPouch TV broth culture and Aptima NAAT for T. vaginalis The diagnostic sensitivities and specificities of the Xpert TV assay for the combined female specimens (urine samples, self-collected vaginal swabs, and endocervical swabs) ranged from 99.5 to 100{\%} and 99.4 to 99.9{\%}, respectively. For male urine samples, the diagnostic sensitivity and specificity were 97.2{\%} and 99.9{\%}, respectively, compared to PIS results derived from the results of broth culture for T. vaginalis and bidirectional gene sequencing of amplicons. Excellent performance characteristics were seen using both female and male specimens. The ease of using the Xpert TV assay should result in opportunities for enhanced screening for T. vaginalis in both men and women and, hopefully, improved control of this infection.",
keywords = "diagnosis, female, male, NAAT, trichomonas",
author = "Schwebke, {Jane R.} and Gaydos, {C. A.} and T. Davis and J. Marrazzo and D. Furgerson and Taylor, {S. N.} and B. Smith and Bachmann, {L. H.} and R. Ackerman and T. Spurrell and Ferris, {Daron Gale} and Burnham, {C. A.} and H. Reno and J. Lebed and D. Eisenberg and P. Kerndt and S. Philip and J. Jordan and N. Quigley",
year = "2018",
month = "2",
day = "1",
doi = "10.1128/JCM.01091-17",
language = "English (US)",
volume = "56",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women

AU - Schwebke, Jane R.

AU - Gaydos, C. A.

AU - Davis, T.

AU - Marrazzo, J.

AU - Furgerson, D.

AU - Taylor, S. N.

AU - Smith, B.

AU - Bachmann, L. H.

AU - Ackerman, R.

AU - Spurrell, T.

AU - Ferris, Daron Gale

AU - Burnham, C. A.

AU - Reno, H.

AU - Lebed, J.

AU - Eisenberg, D.

AU - Kerndt, P.

AU - Philip, S.

AU - Jordan, J.

AU - Quigley, N.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Trichomoniasis is the most prevalent curable sexually transmitted disease (STD). It has been associated with preterm birth and the acquisition and transmission of HIV. Recently, nucleic acid amplification tests (NAAT) have been FDA cleared in the United States for detection of Trichomonas vaginalis in specimens from both women and men. This study reports the results of a multicenter study recently conducted using the Xpert TV (T. vaginalis) assay to test specimens from both men and women. On-demand results were available in as little as 40 min for positive specimens. A total of 1,867 women and 4,791 men were eligible for inclusion in the analysis. In women, the performance of the Xpert TV assay was compared to the patient infected status (PIS) derived from the results of InPouch TV broth culture and Aptima NAAT for T. vaginalis The diagnostic sensitivities and specificities of the Xpert TV assay for the combined female specimens (urine samples, self-collected vaginal swabs, and endocervical swabs) ranged from 99.5 to 100% and 99.4 to 99.9%, respectively. For male urine samples, the diagnostic sensitivity and specificity were 97.2% and 99.9%, respectively, compared to PIS results derived from the results of broth culture for T. vaginalis and bidirectional gene sequencing of amplicons. Excellent performance characteristics were seen using both female and male specimens. The ease of using the Xpert TV assay should result in opportunities for enhanced screening for T. vaginalis in both men and women and, hopefully, improved control of this infection.

AB - Trichomoniasis is the most prevalent curable sexually transmitted disease (STD). It has been associated with preterm birth and the acquisition and transmission of HIV. Recently, nucleic acid amplification tests (NAAT) have been FDA cleared in the United States for detection of Trichomonas vaginalis in specimens from both women and men. This study reports the results of a multicenter study recently conducted using the Xpert TV (T. vaginalis) assay to test specimens from both men and women. On-demand results were available in as little as 40 min for positive specimens. A total of 1,867 women and 4,791 men were eligible for inclusion in the analysis. In women, the performance of the Xpert TV assay was compared to the patient infected status (PIS) derived from the results of InPouch TV broth culture and Aptima NAAT for T. vaginalis The diagnostic sensitivities and specificities of the Xpert TV assay for the combined female specimens (urine samples, self-collected vaginal swabs, and endocervical swabs) ranged from 99.5 to 100% and 99.4 to 99.9%, respectively. For male urine samples, the diagnostic sensitivity and specificity were 97.2% and 99.9%, respectively, compared to PIS results derived from the results of broth culture for T. vaginalis and bidirectional gene sequencing of amplicons. Excellent performance characteristics were seen using both female and male specimens. The ease of using the Xpert TV assay should result in opportunities for enhanced screening for T. vaginalis in both men and women and, hopefully, improved control of this infection.

KW - diagnosis

KW - female

KW - male

KW - NAAT

KW - trichomonas

UR - http://www.scopus.com/inward/record.url?scp=85054934782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054934782&partnerID=8YFLogxK

U2 - 10.1128/JCM.01091-17

DO - 10.1128/JCM.01091-17

M3 - Article

VL - 56

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 2

ER -